 NEW HAVEN, Conn. , Aug. 9, 2022 PRNewswire -- Trevi Therapeutics, Inc. NASDAQ: TRVI, a clinical-stage biopharmaceutical company developing an investigational therapy HaduvioTM oral nalbuphine ER for the treatment of prurigo nodularis PN and chronic cough in adults with idiopathic pulmonary fibrosis IPF, today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit In-person Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants. 